The immunologic consequences of prolonged infusions of rIL-2 in doses that produce physiologic serum concentrations of this cytokine were investigated. rIL Invest. 1993. 91:123-132.)
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cognate antigen, IL-2 promotes proliferation and differentiation of helper T cells, cytotoxic T cells, and B cells ( 1, 2) . Consequently, IL-2 participates in both cell-mediated immunity and humoral immunity, and is probably necessary for both primary and secondary adaptive immune responses. IL-2 may also augment innate or "natural" immunity by stimulating natural killer (NK)' cells (3, 4) and monocytes (5, 6) . Furthermore, IL-2 can induce the classic signs of delayed-type hypersensitivity even in the absence of specific antigen (7) . Commensurate with the crucial involvement of IL-2 in immune responses, congenital absence of IL-2 production in humans causes a severe combined immune deficiency with lifethreatening infections ( 8, 9) . Replacement therapy with recombinant IL-2 (rIL-2) can be effective treatment for this disorder (8) .
The diverse effects of IL-2 are mediated through specific cell surface receptors on lymphocytes, monocytes, and other cell types ( 10) . The IL-2R is comprised ofat least two subunits (10) . The intermediate affinity IL-2R is a 70-75-kD protein that binds IL-2 with an equilibrium Kd of -1 nM; IL-2R p75 can initiate intracellular signal transduction after IL-2 binding ( 11) . The low affinity IL-2R (p55 or CD25) is a 55-kD protein that binds IL-2 with a Kd of -10 nM. IL-2R p55 has not been shown to mediate internalization ofIL-2 or signal transduction by itself. Expressed together on the cell surface, the p75 and p55 chains can associate noncovalently to form a heterodimer that binds IL-2 with high affinity (Kd, -10 pM). Most resting T cells and B cells express neither IL-2R p75 nor p55 and do not respond to exogenous IL-2 ( 10 ). However, after activation by antigen or mitogens, T cells and B cells express high affinity IL-2R heterodimers and proliferate in an IL-2-dependent fashion (10, 11) . By comparison, almost all resting NK cells in human peripheral blood constitutively express isolated IL-2R p75 chains (12) (13) (14) . Thus, NK cells can be activated by nanomolar concentrations of IL-2 in the absence ofadditional stimuli. Since NK cells comprise -10% of PBL, as many as 109 circulating lymphocytes are potentially immediately responsive to IL-2.
The predominant therapeutic use of IL-2 to date has been as an immunostimulant in patients with cancer ( 15, 16) . Based on the paradigms of cytotoxic chemotherapy, IL-2 has been administered in progressively higher doses to define the maximally tolerated dose ( 17, 18) , and bolus intravenous infusions of 15-150 x 106 U (1-10 mg) of IL-2 have been used in most subsequent clinical trials ( 15, 16) . Approximately 15-20% of patients with advanced renal cell carcinoma or melanoma dem-onstrate objective tumor responses after "high dose" IL-2 therapy. Unfortunately, such treatment is associated with lifethreatening toxicities, including severe hypotension, pulmonary edema, renal failure, cardiac arrhythmias, and neurologic dysfunction ( 19, 20) . It is unclear whether beneficial responses can be induced by lower, more physiologic doses of IL-2 that would not lead to such severe systemic toxicity.
We recently published the preliminary results of a phase I trial of rIL-2 given in low doses (0.5-6.0 X 105 U/M2 per d; 3.3-40 ,ug/m2 per d) by continuous intravenous infusion for 3 mo to patients with advanced cancer (21 with the approval of the Human Subjects Protection Committee, Dana-Farber Cancer Institute (Boston, MA). All patients gave informed consent for participation in this study. Patient characteristics and toxicities have been described elsewhere (21) . Blood specimens were collected at weekly or biweekly intervals in heparinized 60-cm3 syringes, and PBMC were immediately separated by Ficoll-Hypaque density gradient centrifugation. Cells were washed three times and resuspended in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY) supplemented with 5% human antibody serum for phenotypic and functional assays. Aliquots of PBMC were also cryopreserved in liquid nitrogen for later use in proliferation and cytotoxicity assays. Blood specimens were also obtained periodically for determinations of complete blood counts, serum chemistries, and serum IL-2 levels.
Analysis ofcellsurface antigens. Single-and two-color immunofluorescence analysis was performed using FITC-and phycoerythrin (PE)-conjugated murine mAb as previously described (22 Cytotoxicity assays. NK cytolytic activity was measured using standard 4-h 5'Cr-release assays as previously described (23). 5,000 5'Cr-labeled target cells were added to wells of V-bottom 96-well microtiter plates, and effector cells were plated in triplicate to yield various effector to target (E/T) ratios. Patient PBMC were assayed for cytotoxicity immediately after separation from peripheral blood or after overnight (18-h) incubation at 37°C in media alone or in media containing various concentrations ( 10 pM-10 nM) of rIL-2. Target cells included K562 (an NK-sensitive human myeloid leukemia cell line), COLO 205 (an NK-resistant human colon adenocarcinoma cell line), and P815 (an NK-resistant murine mastocytoma cell line). Antibody-dependent cellular cytotoxicity (ADCC) assays were performed against P815 cells preincubated with either medium alone or with a 1:100 dilution of polyclonal rabbit anti-mouse lymphocyte serum (Accurate Chemical & Scientific Corp., Westbury, NY) as previously described (23) .
Proliferation assays. Cryopreserved patient PBMC were thawed, stained with PE-conjugated CD56 mAb, and sorted into CD56+ and CD56-subsets by standard methods using flow cytometry. PBMC from healthy volunteer donors were isolated by Ficoll-Hypaque density gradient centrifugation, enriched for NK cells by negative selection using immunomagnetic beads, and sorted into CD56dim and CD56bright subsets by flow cytometry as previously described (23) . Lymphocyte subsets were plated at 30,000 cells per well in 96-well U-bottom microtiter plates and cultured at 37°C; 1 ACi oftritiated thymidine was added to each well after 4 d. Samples were collected 18 h later using a cell harvester, and thymidine incorporation was determined using a liquid scintillation counter as previously described (23) .
Measurement of serum IL-2 concentrations. Serum samples were assayed for IL-2 using an IL-2 enzyme immunoassay kit from Advanced Magnetics, Inc. (Cambridge, MA). Each sample was assayed in duplicate (undiluted or diluted 1:2, 1:4, and 1:8) and compared to a standard curve using homogeneous rIL-2 (Takeda Chemical Industries, Ltd., Osaka, Japan). The lower limit of detection in this assay is 10 pM.
Results
Changes in lymphocyte subsets during continuous infusion rIL-2. Phenotypic analyses of T cell, B cell, and NK cell populations were performed every 7-14 d while patients were receiving rIL-2. Quantitative changes in circulating NK (CD56+) cells are summarized in Fig. 1 Fig. 1 B) . Additional studies were per- (Fig. 2, A-D) .
CD 16 (FcyRIII) is expressed by the majority ofhuman NK cells and is the receptor that triggers NK cell ADCC (27, 28 Effects ofrIL-2 infusion on non-MHC-restricted cytotoxic T lymphocytes. A small subset of resting CD3 + cells expresses the CD56 antigen at low density; these unique T cells comprise -2% of normal PBL (30) . CD56+ CD3+ cells exhibit the morphology of large granular lymphocytes, mediate spontaneous non-MHC-restricted cytotoxicity when freshly isolated, and demonstrate augmented lysis of NK-resistant tumor cell lines after short-term incubation in nanomolar concentrations ofrIL-2 (30) . While detected in virtually all patients in varying percentages before the initiation oftherapy, this population did not expand during continuous low dose rIL-2 infusion. This can be best appreciated in one patient with an unusually high percentage of CD56+ CD3+ non-MHC-restricted T cells before treatment (Fig. 5) . The percentage of CD56+ T cells progressively diminishes as the absolute number of CD56+ CD3-NK cells selectively expands during continuous infusion low dose rIL-2 therapy. Similar results were obtained with all patients treated on this study (not shown). Thus CD56+ CD3+ lymphocytes, like conventional CD56-CD3+ T cells, do not appear to express high affinity IL-2R or to proliferate in vivo in the presence of low concentrations of IL-2.
Effects ofIL-2 infusion on cytolytic activity ofNK cells. The cytolytic activity of PBMC against both NK sensitive (K562) and NK resistant (COLO 205) target cells was examined periodically during the course ofrIL-2 infusion. A gradual increase in cytotoxicity against K562 target cells was detected during IL-2 therapy, generally correlating with the degree ofexpansion ofcirculating NK cells (21 ) . (31, 32) . Further studies were undertaken to determine whether the cytolytic activity of NK cells expanded in vivo by low dose rIL-2 infusion could be further enhanced by incubation with rIL-2 in vitro. Fig. 6 demonstrates results obtained using PBMC from a representative patient after 8 wk of continuous rIL-2 infusion at 6.0 x I05 U/M2 perd. PBMC incubated overnight in medium alone demonstrated only minor cytotoxicity against NK-resistant target cells, and the presence of low concentrations of IL-2 (10 pM) did not enhance cytotoxicity. Cytotoxicity was enhanced after incubation of PBMC with 100 pM IL-2, but this was evident only at the higher effector/target cell ratios. Incubation with higher concentrations of IL-2 ( 1-10 nM) produced markedly enhanced killing of the NK-resistant target, even at low effector/target ratios.
ADCC by PBMC was also tested during the course of rIL-2 infusion. PBMC isolated before low dose rIL-2 infusion failed to demonstrate any significant lysis ofthe P815 murine mastocytoma cell line in the absence (Fig. 7 A) or presence (Fig. 7 B) ofthe polyclonal rabbit anti-mouse lymphocyte serum; further incubation with varying concentrations of exogenous rIL-2 also failed to induce killing of P815 target cells. After in vivo expansion of CD56+ cells by low dose rIL-2 infusion for 6-8 wk, no significant cytotoxicity was seen in the absence of polyclonal rabbit anti-mouse lymphocyte serum. Despite further stimulation with rIL-2 in vitro, minimal cytotoxicity occurred even at the highest concentration of IL-2 (10 nM) (Fig. 7 C) . After addition of polyclonal rabbit anti-mouse lymphocyte serum and exogenous IL-2 (Fig. 7 D) , however, the expanded CD56+ cells exhibited a high degree of ADCC. As ( 15, 16) . The immunologic and clinical effects of high dose IL-2 therapy contrast markedly with those seen in our trial. High dose therapy commonly causes a profound lymphopenia followed by rebound lymphocytosis comprised of both T cells and NK cells ( 17, 37, 38) . Most human NK cells (12) (13) (14) and monocytes (6) constitutively express isolated IL-2R p75 chains, and nanomolar concentrations of IL-2 can induce the secretion of several cytokines by these cells (6, 28, 36, 39) . The T cell activation detected in patients receiving high dose IL-2 is likely caused by secondary cytokines derived from activated NK cells and monocytes, rather than directly caused by rIL-2 itself. Indeed, PBMC from patients receiving high dose IL-2 infusions demonstrate enhanced expression of mRNA for several cytokines, including IL-1, IL-5, IL-6, INF-'y and tumor necrosis factor, and elevated blood levels of these cytokines can be detected in some patients after IL-2 therapy (33) (34) (35) . Furthermore, such cytokines may contribute to the severe toxicities ofhigh dose IL-2 therapy, including hypotension (40) and the vascular leak syndrome (41 ) (27, 28) , so that there is no obvious advantage to expanding individual clones of mature NK cells. Therefore, the demand for increased numbers of NK cells could be met by increasing marrow production from immature progenitors. This might also explain the apparently limited proliferative potential of the vast majority of mature peripheral blood NK cells (29, 36) .
Our results indicate that small subpopulations of lymphocytes can be selectively and profoundly expanded by prolonged infusion of low dose rIL-2. This study strongly suggests that T cells express functional high affinity IL-2R for only a limited time after antigen activation, while NK cells can respond to IL-2 without known previous antigen activation and for an apparently unlimited period of time. Attempts must now be made to identify patients who might benefit from the expansion of these cytotoxic lymphocytes. For example, patients with certain hematologic malignancies have a high risk ofrecurrent disease despite myeloablative chemoradiotherapy and bone marrow transplantation. Recent studies have shown that prolonged low dose rIL-2 therapy can be well tolerated after either autologous or T cell-depleted allogeneic bone marrow transplantation (49) . Intermittent infusions of higher doses of IL-2 might also be administered to activate expanded NK cells via IL-2R p75, in hopes of improving the antitumor activity of these cells. Furthermore, this approach could be combined with serotherapy using mAb reactive with tumor cells or viruses, since most ofthe expanded NK cells express the FcyRIII (CD16) and can mediate ADCC. Clinical trials to evaluate these approaches are currently underway. The design of our IL-2 regimen was based on the pharmacokinetics of IL-2, the binding affinities of the IL-2R, and the known distribution of IL-2R on lymphocyte subsets. Further rational clinical trials with IL-2 and other cytokines could be undertaken using fundamental principles of immunology and endocrinology rather than the paradigms of cytotoxic chemotherapy.
